Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | TMPRSS2 | O15393 | 4/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 6/20 | 0.37 |
| ▸ | KCNA1 | Q09470 | 2/20 | 0.36 |
| ▸ | KCNAB1 | Q14722 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13009363 | 1.00 | SYK (0.40) | SYKTMPRSS2DGAT1ROCK2NAMPT | |
| SCHEMBL1187908 | 1.00 | SYK (0.40) | SYKTMPRSS2DGAT1ROCK2NAMPT | |
| SCHEMBL1188546 | 0.92 | SYK (0.39) | SYKTMPRSS2ROCK2NAMPTKCNA1 | |
| SCHEMBL1188550 | 0.92 | SYK (0.39) | SYKTMPRSS2ROCK2NAMPTKCNA1 | |
| SCHEMBL10004460 | 0.91 | TMPRSS2 (0.41) | SYKTMPRSS2DGAT1ROCK2NAMPT | |
| SCHEMBL10004457 | 0.91 | TMPRSS2 (0.41) | SYKTMPRSS2DGAT1ROCK2NAMPT | |
| SCHEMBL1188471 | 0.91 | KCNA1 (0.40) | SYKTMPRSS2DGAT1ROCK2NAMPT | |
| SCHEMBL1188468 | 0.91 | KCNA1 (0.40) | SYKTMPRSS2DGAT1ROCK2NAMPT | |
| SCHEMBL10004792 | 0.90 | NPC1 (0.48) | TMPRSS2DGAT1NAMPTNPC1CASP3 | |
| SCHEMBL10004790 | 0.90 | NPC1 (0.48) | TMPRSS2DGAT1NAMPTNPC1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735425-B2 | Tetrahydroisoquinoline derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2256105-B1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20110034481-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2256105-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034481-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DGAT1, DGAT2, DLAT | SYK 4151/4885TMPRSS2 2446/4885DGAT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.